Journal: Molecular Therapy
Article Title: siRNA for REST ameliorates symptoms in ALS mice and serum REST predicts disease prognosis and survival in ALS patients
doi: 10.1016/j.ymthe.2025.10.039
Figure Lengend Snippet: Serum levels and prognostic value of REST protein in ALS patients (A) ELISA assay results showing REST protein levels in the serum of ALS patients ( n = 56), compared with healthy controls (Ctrl) ( n = 23). ∗∗ p < 0.01 vs. control by Student’s t test. (B) Kaplan-Meier analysis of tracheostomy-free survival in ALS patients stratified according to the median serum REST protein levels. Patients with REST levels above the median, represented in red, exhibit a significantly worse prognosis than patients with levels below the median, shown in light green. (C and D) Univariate and multivariate Cox proportional hazard models assessing the prognostic value of increased serum REST levels, adjusted for bulbar onset type, sex, progression rate, and age at serum sampling. Whiskers represent the 95% confidence interval (CI). ∗ p < 0.05, ∗∗ p < 0.01.
Article Snippet: Serum REST level was quantified by a human-specific ELISA kit specific for REST (Cusabio, American Research Products, Waltham, MA).
Techniques: Enzyme-linked Immunosorbent Assay, Control, Sampling